FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W897149089> ?p ?o ?g. }

• W897149089 abstract "Background: The addition of bisphosphonates to adjuvant systemic therapy reduces bone metastases and improves survival in postmenopausal patients with early breast cancer. We have conducted four randomised trials of neoadjuvant chemotherapy (CT) +/- zoledronic (ZA) in stage II/III breast cancer to investigate the potential for enhancing pathological response within the breast and axilla. We report here a meta-analysis of these studies to enable more reliable evaluation of treatment effects and investigate activity in pre-defined subgroups of interest. Methods: Individual patient data from four prospective randomized clinical trials reporting the effect of the addition of ZA on pathological response after neoadjuvant CT were pooled. Primary outcomes were pathological complete response in the breast (pCRb) and in the breast and lymph nodes (pCR). A fixed effects Mantel-Haenszel meta-analysis was performed using odds ratios (OR) from multivariate analyses in each study correcting for T-status and ER-status after testing for heterogeneity. Predefined subgroup analyses were performed for postmenopausal women and patients with triple-negative breast cancer. Results: pCRb and pCR data were available in 736 and 553 women respectively. A summary of results is shown in the table below. In the total study population, ZA addition to neoadjuvant CT did not increase pCRb/pCR rates (12.9% for CT only vs. 16.0% with CT+ ZA; OR 1.34, 95% C.I. 0.86-2.08). However, in postmenopausal women, the addition of ZA resulted in a doubling of the pCRb rate (8.5% for CT only vs. 17.0% with CT+ ZA; OR 2.72, 95% C.I. 1.15-6.42) and pCR rate (7.8% for CT only vs. 13.6% with CT+ ZA; OR 2.48, 95% C.I. 0.80-7.69). There was significant interaction between menopausal status and ZA benefit (P for interaction=0.047). In patients with triple-negative breast cancer a trend was observed favouring CT+ZA. Conclusion: This meta-analysis shows that no overall benefit from the addition of ZA to neoadjuvant CT. However, as has been seen in the adjuvant setting, the addition of ZA to CT in postmenopausal women with early breast cancer appears to specifically increase the effects of CT with increases in pCRb and pCR. Further translational research is warranted to explore the mechanism of these observations and the potential treatment interaction with menopause. Citation Format: Judith R Kroep, Ayoub Charehbili, Rob E Coleman, Rebecca L Aft, Yoshie Hasegawa, Gerrit-Jan Liefers, Matthew C Winter, Katherine N Weilbaecher, Kohei Akazawa, Samantha Hinsley, Hein Putter, Hans WR Nortier, Norio Kohno. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-11-04." @default.
• W897149089 created "2016-06-24" @default.
• W897149089 creator A5010512189 @default.
• W897149089 creator A5015062076 @default.
• W897149089 creator A5015398820 @default.
• W897149089 creator A5031880856 @default.
• W897149089 creator A5039094816 @default.
• W897149089 creator A5054757298 @default.
• W897149089 creator A5063285199 @default.
• W897149089 creator A5063709513 @default.
• W897149089 creator A5073613763 @default.
• W897149089 creator A5081645076 @default.
• W897149089 creator A5084388857 @default.
• W897149089 creator A5084823182 @default.
• W897149089 creator A5089623425 @default.
• W897149089 date "2015-04-30" @default.
• W897149089 modified "2023-10-14" @default.
• W897149089 title "Abstract P3-11-04: Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials" @default.
• W897149089 doi "https://doi.org/10.1158/1538-7445.sabcs14-p3-11-04" @default.
• W897149089 hasPublicationYear "2015" @default.
• W897149089 type Work @default.
• W897149089 sameAs 897149089 @default.
• W897149089 citedByCount "0" @default.
• W897149089 crossrefType "proceedings-article" @default.
• W897149089 hasAuthorship W897149089A5010512189 @default.
• W897149089 hasAuthorship W897149089A5015062076 @default.
• W897149089 hasAuthorship W897149089A5015398820 @default.
• W897149089 hasAuthorship W897149089A5031880856 @default.
• W897149089 hasAuthorship W897149089A5039094816 @default.
• W897149089 hasAuthorship W897149089A5054757298 @default.
• W897149089 hasAuthorship W897149089A5063285199 @default.
• W897149089 hasAuthorship W897149089A5063709513 @default.
• W897149089 hasAuthorship W897149089A5073613763 @default.
• W897149089 hasAuthorship W897149089A5081645076 @default.
• W897149089 hasAuthorship W897149089A5084388857 @default.
• W897149089 hasAuthorship W897149089A5084823182 @default.
• W897149089 hasAuthorship W897149089A5089623425 @default.
• W897149089 hasConcept C121608353 @default.
• W897149089 hasConcept C126322002 @default.
• W897149089 hasConcept C143998085 @default.
• W897149089 hasConcept C168563851 @default.
• W897149089 hasConcept C2776326535 @default.
• W897149089 hasConcept C2776694085 @default.
• W897149089 hasConcept C2778292576 @default.
• W897149089 hasConcept C2781190966 @default.
• W897149089 hasConcept C2908647359 @default.
• W897149089 hasConcept C530470458 @default.
• W897149089 hasConcept C71924100 @default.
• W897149089 hasConcept C95190672 @default.
• W897149089 hasConcept C99454951 @default.
• W897149089 hasConceptScore W897149089C121608353 @default.
• W897149089 hasConceptScore W897149089C126322002 @default.
• W897149089 hasConceptScore W897149089C143998085 @default.
• W897149089 hasConceptScore W897149089C168563851 @default.
• W897149089 hasConceptScore W897149089C2776326535 @default.
• W897149089 hasConceptScore W897149089C2776694085 @default.
• W897149089 hasConceptScore W897149089C2778292576 @default.
• W897149089 hasConceptScore W897149089C2781190966 @default.
• W897149089 hasConceptScore W897149089C2908647359 @default.
• W897149089 hasConceptScore W897149089C530470458 @default.
• W897149089 hasConceptScore W897149089C71924100 @default.
• W897149089 hasConceptScore W897149089C95190672 @default.
• W897149089 hasConceptScore W897149089C99454951 @default.
• W897149089 hasLocation W8971490891 @default.
• W897149089 hasOpenAccess W897149089 @default.
• W897149089 hasPrimaryLocation W8971490891 @default.
• W897149089 hasRelatedWork W13998030 @default.
• W897149089 hasRelatedWork W14561912 @default.
• W897149089 hasRelatedWork W15495912 @default.
• W897149089 hasRelatedWork W16162527 @default.
• W897149089 hasRelatedWork W17538324 @default.
• W897149089 hasRelatedWork W20132274 @default.
• W897149089 hasRelatedWork W4741852 @default.
• W897149089 hasRelatedWork W518170 @default.
• W897149089 hasRelatedWork W5453825 @default.
• W897149089 hasRelatedWork W19634549 @default.
• W897149089 isParatext "false" @default.
• W897149089 isRetracted "false" @default.
• W897149089 magId "897149089" @default.
• W897149089 workType "article" @default.